$DXCM

Heller Bridgette P sold $89K of DXCM

Heller Bridgette P sold 1,012 shares of DEXCOM INC (DXCM) at $88.29 on 2026-08-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Heller Bridgette P
Published Aug 13, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DXCM
Neutral
high confidence
Mentioned
$DXCM
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DXCMNeutralLow
01

Why it matters

The only new fact is the director’s sale size, price, and that it was executed under a pre-arranged 10b5-1 plan; no business or financial updates are included.

02

Market read

Traders may note the sale for sentiment monitoring, but it is unlikely to change valuation without additional company-specific news.

03

What to watch

10b5-1 plans can be triggered regardless of near-term outlook; the filing does not reveal intent beyond the scheduled trading window.

Relevance 2/10Novelty 3/10Timing: filed 2026-08-13, sale dated 2026-08-12

Background

The article is a SEC Form 4 insider transaction disclosure for DexCom.

Company-level read

Ticker impact

$DXCMNeutralHigh confidence
Context

DexCom director Heller Bridgette P sold 1,012 shares at $88.29 on 2026-08-12 under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this filing alone.

Evidence & confidence

The filing is a Form 4 insider open-market sale, explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying guidance, contract, or operational change disclosed.

Market effects

Minimal, as this is an individual director’s 10b5-1 sale with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

A cluster of insider sales (if corroborated by other recent Form 4s) could still reflect private caution, even when executed via 10b5-1.

Key entities

  • DexCom Inc

    Subject of the Form 4 insider sale disclosure.

  • Heller Bridgette P

    Director who sold 1,012 shares at $88.29 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DXCMMed

DexCom (DXCM) Tests Its Execution Story After Expanding Its CFO Role

DexCom (DXCM) promoted its CFO, Jereme Sylvain, to also serve as COO, expanding his role to include global operations and quality. The company's stock has seen volatility, with a 3.1% drop over the past week and a 30.2% gain year-to-date. Analysts suggest a fair value of $94.48, indicating a modest discount at the current price of $86.62.

$DXCMLow

Did COO Appointment Just Shift DexCom (DXCM) Investment Narrative?

DexCom (DXCM) appointed Jereme Sylvain as COO and Glenn Boehnlein to its board, focusing on execution, supply chain, and capital allocation. The company projects $6.8B revenue and $1.5B earnings by 2029, with analysts expecting 11.2% yearly growth. Investors watch leadership changes for impact on expansion and execution.

$DXCMLow

DexCom (DXCM) Reshuffles Leadership, Is The Stock Fully Valued?

DexCom (DXCM) promoted CFO Jereme Sylvain to CFO and COO, added Glenn S. Boehnlein to its board. The stock trades at $87.93, up 21.33% over 90 days and 32.15% year-to-date. Analysts estimate fair value at $94.12, with growth driven by expanded insurance coverage and global market penetration. The company trades at a P/E of 33.2x, above sector and peer averages.

$DXCMMed

Dexcom CFO to expand into COO role

Dexcom's CFO, Jereme Sylvain, will also take on the role of COO, overseeing global operations and quality teams. The move comes as the company develops its G8 continuous glucose monitor and expands its Stelo wearable. Previous COO Jake Leach became CEO in January.

$RMDMedAI 8/10

Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest

ResMed (RMD) and peers reported Q2 earnings, with revenues beating estimates by 1.4% but next quarter's guidance below. RMD's revenue grew 8.6% YoY, meeting expectations, while iRhythm (IRTC) saw 20.1% growth, exceeding estimates. Insulet (PODD) and DexCom (DXCM) also reported, with mixed results. Stocks have declined since earnings, with RMD down 2.3% and IRTC down 13%.